Original paper
PB1933 CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE‐CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL‐WORLD DATA
Abstract
Background: Tyrosine kinase inhibitors (TKIs) have been standard‐of‐care for patients with chronic myeloid leukemia (CML) and improvements with TKIs have been obtained in survival rates. In Turkey, imatinib is the only reimbursed TKI for first line treatment and second generation TKI's are reserved for later lines. Some concerns such as TKI tolerability, adverse event profile, patient comorbidities, and concomitant drug use may affect the choice...
Paper Details
Title
PB1933 CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE‐CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL‐WORLD DATA
Published Date
Jun 1, 2019
Journal
Volume
3
Issue
S1
Pages
879 - 879
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History